Spring is in the air, and the annual NCAA March Madness college basketball tournament has once again captivated the nation. Of course, that also means that Cinderella stories like Wichita State have busted brackets of would-be basketball prognosticators.

Here at The Motley Fool, we decided to stick with what we know -- trading our basketball picks in for stock picks. We formed our own bracket filled with the top big pharma and big biotech stocks in a winner-take-all tournament determined by the collective intelligence of our CAPS community.

This Elite 8 matchup features a heavyweight bought between Celgene and Gilead. Watch and find out which stock gets eliminated and which will advance to the next round.

Max Macaluso, Ph.D. has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.

The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.